African Multi-Site 2-Year Neuropsychological Study of School-Age Children Perinatally Infected, Exposed, and Unexposed to Human Immunodeficiency Virus.
executive function
learning
motor proficiency
neuropsychology
pediatric HIV
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
23 10 2020
23 10 2020
Historique:
received:
13
08
2019
accepted:
31
10
2019
pubmed:
19
12
2019
medline:
29
4
2021
entrez:
19
12
2019
Statut:
ppublish
Résumé
Children living with human immunodeficiency virus (HIV) are at neuropsychological risk for cognitive and motor dysfunction. However, few prospective, multi-site studies have evaluated neuropsychological outcomes longitudinally among perinatally infected African children who received early antiretroviral treatment (ART). We enrolled 611 children aged 5 to 11 years at 6 sites (South Africa [3], Zimbabwe, Malawi, Uganda). Of these, there were 246 children living with HIV (HIV+) who were initiated on ART before 3 years of age in a prior clinical trial comparing nevirapine to lopinavir/ritonavir (International Maternal Pediatric Adolescent Acquired Immunodeficiency Syndrome Clinical Trials [IMPAACT] P1060); 183 age-matched, exposed but uninfected (HEU) children; and 182 unexposed and uninfected (HUU) children. They were compared across 3 assessment time points (Weeks 0, 48, and 96) on cognitive ability (Kaufman Assessment Battery for Children, second edition [KABC-II]), attention/impulsivity (Tests of Variables of Attention [TOVA]), motor proficiency (Bruininks-Oseretsky Test, second edition [BOT-2]), and on the Behavior Rating Inventory of Executive Function (BRIEF). The cohorts were compared using linear mixed models, adjusting for site, child's age and sex, and selected personal/family control variables. The HIV+ cohort performed significantly worse than the HEU and HUU cohorts for all KABC-II, TOVA, and BOT-2 performance outcomes across all 3 time points (P values < .001). The HUU and HEU cohorts were comparable. For the KABC-II planning/reasoning subtests, the HIV+ children showed less improvement over time than the HUU and HEU groups. The groups did not differ significantly on the BRIEF. Despite initiation of ART in early childhood and good viral suppression at the time of enrollment, the HIV+ group had poorer neuropsychological performance over time, with the gap progressively worsening in planning/reasoning. This can be debilitating for self-management in adolescence.
Sections du résumé
BACKGROUND
Children living with human immunodeficiency virus (HIV) are at neuropsychological risk for cognitive and motor dysfunction. However, few prospective, multi-site studies have evaluated neuropsychological outcomes longitudinally among perinatally infected African children who received early antiretroviral treatment (ART).
METHODS
We enrolled 611 children aged 5 to 11 years at 6 sites (South Africa [3], Zimbabwe, Malawi, Uganda). Of these, there were 246 children living with HIV (HIV+) who were initiated on ART before 3 years of age in a prior clinical trial comparing nevirapine to lopinavir/ritonavir (International Maternal Pediatric Adolescent Acquired Immunodeficiency Syndrome Clinical Trials [IMPAACT] P1060); 183 age-matched, exposed but uninfected (HEU) children; and 182 unexposed and uninfected (HUU) children. They were compared across 3 assessment time points (Weeks 0, 48, and 96) on cognitive ability (Kaufman Assessment Battery for Children, second edition [KABC-II]), attention/impulsivity (Tests of Variables of Attention [TOVA]), motor proficiency (Bruininks-Oseretsky Test, second edition [BOT-2]), and on the Behavior Rating Inventory of Executive Function (BRIEF). The cohorts were compared using linear mixed models, adjusting for site, child's age and sex, and selected personal/family control variables.
RESULTS
The HIV+ cohort performed significantly worse than the HEU and HUU cohorts for all KABC-II, TOVA, and BOT-2 performance outcomes across all 3 time points (P values < .001). The HUU and HEU cohorts were comparable. For the KABC-II planning/reasoning subtests, the HIV+ children showed less improvement over time than the HUU and HEU groups. The groups did not differ significantly on the BRIEF.
CONCLUSIONS
Despite initiation of ART in early childhood and good viral suppression at the time of enrollment, the HIV+ group had poorer neuropsychological performance over time, with the gap progressively worsening in planning/reasoning. This can be debilitating for self-management in adolescence.
Identifiants
pubmed: 31848582
pii: 5649306
doi: 10.1093/cid/ciz1088
pmc: PMC7755090
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e105-e114Subventions
Organisme : NIAID NIH HHS
ID : UM1 AI069423
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069530
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069453
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068632
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI106716
Pays : United States
Organisme : NIMH NIH HHS
ID : R21 MH083308
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069463
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068616
Pays : United States
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
J Int AIDS Soc. 2017 Jun 14;20(1):21412
pubmed: 28664684
Child Neuropsychol. 2019 May;25(4):466-481
pubmed: 30105934
Glob Ment Health (Camb). 2015 May 29;2:e6
pubmed: 28596854
J Int AIDS Soc. 2013 Jun 18;16:18593
pubmed: 23782478
J Int AIDS Soc. 2018 May;21(5):e25106
pubmed: 29722482
AIDS Care. 2020 Apr;32(4):486-494
pubmed: 31462095
J Int AIDS Soc. 2013 Jun 18;16:18603
pubmed: 23782482
Pediatr Infect Dis J. 2013 May;32(5):501-8
pubmed: 23263176
Curr HIV/AIDS Rep. 2016 Dec;13(6):318-327
pubmed: 27783207
Clin Infect Dis. 2016 Oct 15;63(8):1113-1121
pubmed: 27439527
Mod Probl Pharmacopsychiatry. 1974;7(0):79-110
pubmed: 4607278
AIDS Res Hum Retroviruses. 2016 Aug;32(8):743-55
pubmed: 27045714
J Int AIDS Soc. 2018 Feb;21 Suppl 1:
pubmed: 29485735
N Engl J Med. 2012 Jun 21;366(25):2380-9
pubmed: 22716976
N Engl J Med. 2010 Oct 14;363(16):1510-20
pubmed: 20942667
J Pediatr Infect Dis. 2018 Sep;13(3):185-201
pubmed: 30100780
J Clin Epidemiol. 1995 May;48(5):657-66
pubmed: 7537327
AIDS. 2018 Jan 14;32(2):189-204
pubmed: 29112069
AIDS. 2018 Nov 28;32(18):2749-2757
pubmed: 30289800
Behav Sci. 1974 Jan;19(1):1-15
pubmed: 4808738
AIDS Care. 2012;24(8):953-62
pubmed: 22519762
AIDS. 2012 Aug 24;26(13):1685-90
pubmed: 22614886
Pediatr Infect Dis J. 2014 Aug;33(8):846-54
pubmed: 25222305